Consistent with this hypothesis, a single dose of TransCon TLR7/8 Agonist in combination with systemic recombinant IL-2 resulted in greater anti-tumor activity in injected and non-injected tumors in an abscopal model, with mice bearing CT26 tumors on both flanks, compared to either single agent treatment alone (Fig. 6B). This evidence concerns the gene IL2 and neoplasm.